Shifu Li, Wenbin Dong, Yingni Yu, Zhibing Yang, Yang Luo, Ying Cai, Yongfen Zhu, Qiang Wu, Qiongfen Li, Shu Su, Rusong Yang
{"title":"中国云南省政府主导、以患者为中心的丙型肝炎患者再参与策略","authors":"Shifu Li, Wenbin Dong, Yingni Yu, Zhibing Yang, Yang Luo, Ying Cai, Yongfen Zhu, Qiang Wu, Qiongfen Li, Shu Su, Rusong Yang","doi":"10.1111/jvh.70028","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Diagnosed but untreated (DBU) hepatitis C virus (HCV) infected patients are a key group for HCV elimination efforts. This study aims to pilot a government-led, multi-sectoral approach to universal patient recall and treatment mobilisation in Yunnan Province, China, to determine if this approach can improve treatment uptake among DBU patients and contribute to HCV elimination. In this quasi-experimental before-and-after study, we analysed all hepatitis C cases reported from 2004 to 2021 in the Yuxi City Center for Disease Control (CDC) database. From July to December 2022, the traditional telephone recall model was used, and from July 2023 to January 2024, Yuxi CDC partnered with local stakeholders to implement a patient-centric strategy to re-engage DBU patients in care. We compared the outcomes between these two approaches. The cooperation model significantly improved HCV case management. The contact rate rose from 29.7% (645/2171) to 58.5% (3813/6520) (<i>χ</i><sup><i>2</i></sup> = 25.743, <i>p</i> < 0.001); the HCV-RNA testing rate increased from 18.9% (122/645) to 86.1% (3283/3813) (<i>χ</i><sup><i>2</i></sup> = 2760.164, <i>p</i> < 0.001); and treatment initiation for positive cases improved from 19.6% (9/46) to 57.8% (884/1530) (<i>χ</i><sup><i>2</i></sup> = 26.555, <i>p</i> < 0.001). In total, 936 patients received treatment, and 92 patients (9.8%) were lost to follow-up 12 weeks post-treatment. Of the remaining 844 patients, 841 (99.6%) achieved SVR12 (sustained virological response12 weeks after therapy, defined as HCV quantitative test below 15 IU/mL), with no significant difference in outcomes between tested and untested genotype groups (<i>χ</i><sup><i>2</i></sup> = 0.123, <i>p</i> = 0.725). This study highlights the substantial advantages of the cooperative model over the traditional approach, notably in contact, testing, and treatment rates, and successful SVR12 outcomes, underscoring the potential for such models in advancing HCV elimination.</p>\n </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Government-Led, Patient-Centric Strategy to Re-Engage Diagnosed but Untreated Hepatitis C Patients in Yunnan Province, China\",\"authors\":\"Shifu Li, Wenbin Dong, Yingni Yu, Zhibing Yang, Yang Luo, Ying Cai, Yongfen Zhu, Qiang Wu, Qiongfen Li, Shu Su, Rusong Yang\",\"doi\":\"10.1111/jvh.70028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Diagnosed but untreated (DBU) hepatitis C virus (HCV) infected patients are a key group for HCV elimination efforts. This study aims to pilot a government-led, multi-sectoral approach to universal patient recall and treatment mobilisation in Yunnan Province, China, to determine if this approach can improve treatment uptake among DBU patients and contribute to HCV elimination. In this quasi-experimental before-and-after study, we analysed all hepatitis C cases reported from 2004 to 2021 in the Yuxi City Center for Disease Control (CDC) database. From July to December 2022, the traditional telephone recall model was used, and from July 2023 to January 2024, Yuxi CDC partnered with local stakeholders to implement a patient-centric strategy to re-engage DBU patients in care. We compared the outcomes between these two approaches. The cooperation model significantly improved HCV case management. The contact rate rose from 29.7% (645/2171) to 58.5% (3813/6520) (<i>χ</i><sup><i>2</i></sup> = 25.743, <i>p</i> < 0.001); the HCV-RNA testing rate increased from 18.9% (122/645) to 86.1% (3283/3813) (<i>χ</i><sup><i>2</i></sup> = 2760.164, <i>p</i> < 0.001); and treatment initiation for positive cases improved from 19.6% (9/46) to 57.8% (884/1530) (<i>χ</i><sup><i>2</i></sup> = 26.555, <i>p</i> < 0.001). In total, 936 patients received treatment, and 92 patients (9.8%) were lost to follow-up 12 weeks post-treatment. Of the remaining 844 patients, 841 (99.6%) achieved SVR12 (sustained virological response12 weeks after therapy, defined as HCV quantitative test below 15 IU/mL), with no significant difference in outcomes between tested and untested genotype groups (<i>χ</i><sup><i>2</i></sup> = 0.123, <i>p</i> = 0.725). This study highlights the substantial advantages of the cooperative model over the traditional approach, notably in contact, testing, and treatment rates, and successful SVR12 outcomes, underscoring the potential for such models in advancing HCV elimination.</p>\\n </div>\",\"PeriodicalId\":17762,\"journal\":{\"name\":\"Journal of Viral Hepatitis\",\"volume\":\"32 6\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Viral Hepatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvh.70028\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Viral Hepatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvh.70028","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
诊断但未经治疗(DBU)的丙型肝炎病毒(HCV)感染患者是HCV消除工作的关键群体。本研究旨在在中国云南省试点政府主导的多部门方法,以普及患者召回和治疗动员,以确定该方法是否可以提高DBU患者的治疗接受度并有助于消除丙型肝炎病毒。在这项准实验前后对比研究中,我们分析了玉溪市疾病控制中心(CDC)数据库中2004年至2021年报告的所有丙型肝炎病例。从2022年7月至12月,采用传统的电话召回模型,从2023年7月至2024年1月,玉溪市疾病预防控制中心与当地利益相关者合作,实施以患者为中心的战略,使DBU患者重新参与护理。我们比较了这两种方法的结果。这种合作模式显著改善了HCV病例管理。接触率由29.7%(645/2171)上升至58.5% (3813/6520)(χ2 = 25.743, p < 0.001);HCV-RNA检出率由18.9%(122/645)上升至86.1% (3283/3813)(χ2 = 2760.164, p < 0.001);阳性病例的开始治疗率由19.6%(9/46)提高至57.8% (884/1530)(χ2 = 26.555, p < 0.001)。共有936例患者接受了治疗,92例患者(9.8%)在治疗后12周失访。在剩余的844例患者中,841例(99.6%)达到SVR12(治疗后12周持续病毒学应答,定义为HCV定量检测低于15 IU/mL),检测和未检测基因型组之间的结果无显著差异(χ2 = 0.123, p = 0.725)。这项研究强调了合作模式相对于传统方法的巨大优势,特别是在接触率、检测率和治疗率以及成功的SVR12结果方面,强调了这种模式在推进HCV消除方面的潜力。
A Government-Led, Patient-Centric Strategy to Re-Engage Diagnosed but Untreated Hepatitis C Patients in Yunnan Province, China
Diagnosed but untreated (DBU) hepatitis C virus (HCV) infected patients are a key group for HCV elimination efforts. This study aims to pilot a government-led, multi-sectoral approach to universal patient recall and treatment mobilisation in Yunnan Province, China, to determine if this approach can improve treatment uptake among DBU patients and contribute to HCV elimination. In this quasi-experimental before-and-after study, we analysed all hepatitis C cases reported from 2004 to 2021 in the Yuxi City Center for Disease Control (CDC) database. From July to December 2022, the traditional telephone recall model was used, and from July 2023 to January 2024, Yuxi CDC partnered with local stakeholders to implement a patient-centric strategy to re-engage DBU patients in care. We compared the outcomes between these two approaches. The cooperation model significantly improved HCV case management. The contact rate rose from 29.7% (645/2171) to 58.5% (3813/6520) (χ2 = 25.743, p < 0.001); the HCV-RNA testing rate increased from 18.9% (122/645) to 86.1% (3283/3813) (χ2 = 2760.164, p < 0.001); and treatment initiation for positive cases improved from 19.6% (9/46) to 57.8% (884/1530) (χ2 = 26.555, p < 0.001). In total, 936 patients received treatment, and 92 patients (9.8%) were lost to follow-up 12 weeks post-treatment. Of the remaining 844 patients, 841 (99.6%) achieved SVR12 (sustained virological response12 weeks after therapy, defined as HCV quantitative test below 15 IU/mL), with no significant difference in outcomes between tested and untested genotype groups (χ2 = 0.123, p = 0.725). This study highlights the substantial advantages of the cooperative model over the traditional approach, notably in contact, testing, and treatment rates, and successful SVR12 outcomes, underscoring the potential for such models in advancing HCV elimination.
期刊介绍:
The Journal of Viral Hepatitis publishes reviews, original work (full papers) and short, rapid communications in the area of viral hepatitis. It solicits these articles from epidemiologists, clinicians, pathologists, virologists and specialists in transfusion medicine working in the field, thereby bringing together in a single journal the important issues in this expanding speciality.
The Journal of Viral Hepatitis is a monthly journal, publishing reviews, original work (full papers) and short rapid communications in the area of viral hepatitis. It brings together in a single journal important issues in this rapidly expanding speciality including articles from:
virologists;
epidemiologists;
clinicians;
pathologists;
specialists in transfusion medicine.